



3-305 Industrial Parkway South
Aurora, Ontario, Canada, L4G 6X7
Phone: (905) 841-2300
Fax: (905) 841-2244
Web: www.helixbiopharma.com

September 9, 2016
NEWS RELEASE

HELIX BIOPHARMA CORP. TO PRESENT AT PRECISION LUNG CANCER WORLD R&D SUMMIT

Therapeutic Strategy Against Tumor Acidity Induced Immune-Suppression: L-DOS47 a Clinical Candidate for Lung Cancer

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that Dr. Heman Chao, Helix’s CSO, will be presenting: *Therapeutic Strategy Against Tumor Acidity Induced Immune-Suppression: L-DOS47 a Clinical Candidate for Lung Cancer* at the Precision Lung Cancer World R&D Summit being held on September 13th and 14th, 2016 at the Royal Sonesta Boston hotel in Boston, Massachusetts.

The presentation will discuss the application of L-DOS47 to break down acidic tumor microenvironment that provides the tumor a defense against body’s natural immune systems. The presentation will further describe the potential utility of L-DOS47 in combination chemotherapies and immunotherapies. A copy of the presentation will be made available on the Company’s website.

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol “HBP”.

Investor Relations

Helix BioPharma Corp.
3-305 Industrial Parkway South
Aurora, Ontario, L4G 6X7
Tel: 905 841-2300
Email: ir@helixbiopharma.com

Forward-Looking Statements and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the potential of Helix’s DOS47 platform and specifically L-DOS47 as a Therapeutic Strategy Against Tumor Acidity Induced Immune-Suppression as a Clinical Candidate for Lung Cancer, which may be identified by words including, without limitation, “will”, “may”, “anticipated”, and other similar expressions, are intended to provide information about management’s current plans and expectations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include those described in Helix's most recent Annual Report, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.
